Exact Sciences Co. (NASDAQ:EXAS) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Exact Sciences Co. (NASDAQ:EXAS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nineteen brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $72.76.

Several research analysts recently weighed in on EXAS shares. TD Cowen raised their target price on Exact Sciences from $82.00 to $86.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Canaccord Genuity Group cut their target price on shares of Exact Sciences from $95.00 to $75.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. The Goldman Sachs Group decreased their price target on shares of Exact Sciences from $75.00 to $65.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. Citigroup cut their price objective on Exact Sciences from $80.00 to $75.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. Finally, Piper Sandler decreased their price target on Exact Sciences from $85.00 to $75.00 and set an "overweight" rating for the company in a research report on Monday, November 11th.

Insider Transactions at Exact Sciences

In other Exact Sciences news, CEO Kevin T. Conroy purchased 19,500 shares of the company's stock in a transaction dated Wednesday, November 13th. The shares were bought at an average price of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the transaction, the chief executive officer now directly owns 1,074,191 shares in the company, valued at $55,159,707.85. This trade represents a 1.85 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.36% of the company's stock.

Institutional Trading of Exact Sciences

Several hedge funds have recently bought and sold shares of EXAS. Fisher Asset Management LLC lifted its position in Exact Sciences by 43.7% in the 4th quarter. Fisher Asset Management LLC now owns 176,637 shares of the medical research company's stock valued at $9,925,000 after acquiring an additional 53,735 shares in the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych boosted its position in shares of Exact Sciences by 33.3% during the fourth quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 24,000 shares of the medical research company's stock worth $1,349,000 after buying an additional 6,000 shares during the period. Proficio Capital Partners LLC bought a new position in shares of Exact Sciences during the fourth quarter worth about $1,604,000. JFG Wealth Management LLC bought a new stake in Exact Sciences in the 4th quarter valued at approximately $255,000. Finally, Skylands Capital LLC grew its stake in shares of Exact Sciences by 2,850.0% during the 4th quarter. Skylands Capital LLC now owns 11,800 shares of the medical research company's stock worth $663,000 after acquiring an additional 11,400 shares in the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Exact Sciences Stock Performance

Shares of NASDAQ:EXAS traded up $1.03 on Friday, hitting $55.78. The company's stock had a trading volume of 1,440,449 shares, compared to its average volume of 2,286,402. The company has a market capitalization of $10.32 billion, a price-to-earnings ratio of -47.67 and a beta of 1.24. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12. Exact Sciences has a 12 month low of $40.62 and a 12 month high of $79.62. The stock's 50-day moving average is $57.75 and its two-hundred day moving average is $60.00.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The company had revenue of $708.66 million during the quarter, compared to analyst estimates of $716.80 million. The firm's quarterly revenue was up 12.8% on a year-over-year basis. On average, equities research analysts forecast that Exact Sciences will post -1.1 EPS for the current year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.